{
    "clinical_study": {
        "@rank": "109448", 
        "acronym": "IMMUNOSEP", 
        "arm_group": [
            {
                "arm_group_label": "Multiple Sclerosis", 
                "arm_group_type": "Experimental", 
                "description": "Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "HLA-A2 patients hospitalized in the  neurology department who are not affected with a neuroimmunological disorder"
            }, 
            {
                "arm_group_label": "Multiple Sclerosis patients  treated", 
                "arm_group_type": "Experimental", 
                "description": "HLA-A2 Multiple Sclerosis patients  treated by Natalizumab therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "Most  experts in the field consider Multiple Sclerosis as the main auto immune disease of\n      the central nervous system. In spite of many works, the data in the literature  concerning\n      the antigens targeted by the CD8+ T-Cell response  are still contradictory and insufficient."
        }, 
        "brief_title": "Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "30 patients distributed in 3 groups of 10 patients with specific inclusion criteria will\n      participate in this trial:\n\n        -  10 MS patients in early disease onset,\n\n        -  10 MS patients under Natalizumab treatment\n\n        -  and control group of 10 patients with other neurological diseases.\n\n      The aim of this clinical trial is to detect the CD8+ myelin specific T-Cells in the blood of\n      Multiple Sclerosis patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Group 1: HLA-A2 patients whose Multiple Sclerosis has just been diagnosed\n\n          -  18 year old and older patients,\n\n          -  HLA-A2 Patients with   Multiple Sclerosis or clinically isolated syndrome at high\n             risk of being affected by Multiple Sclerosis (criteria of spatial scattering\n             according to the 2010 or 2005 McDonald's criteria)\n\n          -  Patients without treatment or  treated with immunomodulating therapy\n\n          -  Patients affiliated to health insurance coverage\n\n          -  Information and comprehensive agreement signed by the patient and the investigator\n\n        Group 2: HLA-A2 patients hospitalized in the  neurology department who are not affected\n        with a neuroimmunological disorder\n\n          -  18 year old and older patients,\n\n          -  HLA-A2 patients hospitalized in the neurology department\n\n          -  Patient not affected by Multiple Sclerosis or a related inflammatory disorder\n\n          -  Affiliated or profitable subject of a national insurance scheme\n\n          -  Patients affiliated to health insurance coverage\n\n          -  Information and comprehensive agreement signed by the patient and the investigator\n\n        Group 3: HLA-A2 Multiple Sclerosis patients  treated by Natalizumab therapy\n\n          -  18 year old and older patients,\n\n          -  HLA-A2 patients with relapsing remitting (RR) MS fulfilling  McDonald 2005 or 2010\n             Multiple Sclerosis diagnostic criteria\n\n          -  Patients  treated by Natalizumab therapy  for at least 3 months\n\n          -  Patients affiliated to health insurance coverage\n\n          -  Information and comprehensive agreement signed by the patient and the investigator\n\n        Exclusion Criteria:\n\n        Group 1 and 3:\n\n          -  Patients undergoing immunosuppressive therapy at present or in the past except\n             Natalizumab\n\n          -  Pregnant women\n\n        Group 2:\n\n          -  Patients undergoing immunosuppressive therapy at present or in the past\n\n          -  Patients affected by Multiple Sclerosis or a related disorder\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142764", 
            "org_study_id": "CHUBX 2013/01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Multiple Sclerosis", 
                    "Multiple Sclerosis patients  treated"
                ], 
                "description": "The blood will be sampled in order to be tested  in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).", 
                "intervention_name": "Blood samples", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)", 
                "intervention_name": "Blood samples", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis", 
            "CD8+ T-cells", 
            "Class I Major Histocompatibility Complex (MHC)", 
            "pentamers"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "jean-christophe.ouallet@chu-bordeaux.fr", 
                "last_name": "Jean-Christophe OUALLET, MD", 
                "phone": "(0)5 56 79 55 21", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "zip": "33076"
                }, 
                "name": "Service de Neurologie - Tripode - H\u00f4pital Pellegrin"
            }, 
            "investigator": {
                "last_name": "Jean-Christophe OUALLET, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).", 
        "overall_contact": {
            "email": "jean-christophe.ouallet@chu-bordeaux.fr", 
            "last_name": "Jean-Christophe OUALLET, MD", 
            "phone": "(0)5 56 79 55 21", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "dieynaba.djigo@chu-bordeaux.fr", 
            "last_name": "Dieynaba DJIGO", 
            "phone": "(0)5 57 57 48 17", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Bordeaux, France", 
            "last_name": "Jean-Christophe OUALLET, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This analysis will enable us to detect CD8+ myelin specific T-cells in the blood of Multiple Sclerosis", 
            "measure": "Analysis of pentamers (> 0,1 % of the CD3 + CD8 + T-cells)  will be statistically compared between the 3 groups of patients.", 
            "safety_issue": "No", 
            "time_frame": "6 months after the inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of attacks relapses and evolution of the Expanded Disability Status Scale from the last 2 years", 
                "measure": "The results will be correlated with the patients clinical", 
                "safety_issue": "No", 
                "time_frame": "6 months after the inclusion"
            }, 
            {
                "description": "MRI activity (load lesions (\u2265 9 lesions or not), gadolinium  enhanced) from the last 2 years", 
                "measure": "The results will be correlated with the patients MRI data", 
                "safety_issue": "No", 
                "time_frame": "6 months after the inclusion"
            }, 
            {
                "measure": "Description of lymphocyte immunophenotyping and dosage of immunoglobulins in patients treated with Natalizumab", 
                "safety_issue": "No", 
                "time_frame": "6 months after the inclusion"
            }
        ], 
        "source": "University Hospital, Bordeaux", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Merck Serono International SA", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "ADERA", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital, Bordeaux", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}